← board
SLXN
distress 6/10 · elevated risk$2.50-1%today-98% from 52w high
Lead: locally advanced pancreatic cancer · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
+473%
Price & events
-88.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-10.1%
1W
-7.7%
1M
-72.8%
3M
-88.5%
6M
-98.1%
1Y
-99.9%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $10.48M
- Volume
- 2.49K
- 52 Week Range
- $2.50 – $149
- Total Shares
- 4.19M
- Float Shares
- 414.62K
- Short %
- 1.56%
- % Held by Insiders
- 24.16%
- % Held by Institutions
- 1.79%
- RVOL
- 0.02x
- Beta
- -0.26
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 1H 2026trial initiationsecondaryPhase 2/3SIL-204 · Initiate Phase 2/3 trialSEC 8-K
- 2026-05-13trial initiationsecondarySIL204 · Initiated GMP clinical supply manufacturing with leading global CDMO.SEC 8-K
- H2 2025trial initiationsecondarySIL-204 · Initiate preclinical studiesSEC 8-K
- H2 2025regulatory submissionFiled (NDA/BLA)SIL-204 · CTA submission in EU for Phase 2/3 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,189,954 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $60 (+2300% upside) · 2 analysts
- 2025-12-15Litchfield HillsBuy
- 2025-03-20Maxim GroupBuy
- 2024-11-01Maxim GroupBuy
Competitors — locally advanced pancreatic cancer
Recent news
- 2026-07-21Silexion Therapeutics Shareholders Approve Capital Structure Changes - TipRanks
- 2026-07-11Silexion Therapeutics (SLXN) Holds Near Support as Trading Remains Subdued - MA Cross Alert - dars.gov.et
- 2026-07-09Price to book forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
- 2026-06-28SLXN Q1 2026 Earnings: EPS Beat Highlights Narrower-than-Expected Loss Amid Development Stage - EBITDA Estimate Trend - dars.gov.et
- 2026-06-25SLXN Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-24Form 13D/A Silexion Therapeutics Corp For: 23 June By Investing.com - Investing.com Nigeria
- 2026-06-24Silexion Therapeutics Warrants (SLXNW) Hold Flat at $0.03 as Range Tightens - Composite Profile - dars.gov.et
- 2026-06-23Silexion gets Germany’s nod for pancreatic cancer trial after Israel - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.